Letrozol Stada

Letrozole, the active ingredient in Letrozol Stada, is an aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women and is marketed in the European Union as a prescription‑only product.

GNH USA supplies Letrozol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company provides bulk and finished‑product solutions to hospitals, oncology centres, pharmacies, research institutions and procurement teams across multiple continents.

Letrozole is an aromatase inhibitor used in the management of hormone‑dependent breast cancer.

- Hormone receptor‑positive breast cancer in postmenopausal women: reduces tumor growth by lowering estrogen levels. - Adjuvant treatment of early‑stage breast cancer: prolongs disease‑free survival after surgery. - Metastatic breast cancer: improves progression‑free survival in advanced disease.

Letrozole may cause a range of adverse reactions.

Common Side Effects: - Hot flashes - Joint pain (arthralgia) - Nausea - Fatigue

Serious or Rare Side Effects: - Severe liver injury - Bone fracture due to decreased bone density - Deep vein thrombosis or pulmonary embolism - Severe allergic reaction (anaphylaxis)

When prescribing Letrozole, clinicians should consider several safety measures.

- Monitor liver function: perform baseline and periodic liver‑function tests. - Assess bone health: consider prophylactic calcium and vitamin D supplementation. - Evaluate cardiovascular risk: monitor lipid profile regularly. - Avoid use in pregnancy: contraindicated in women of childbearing potential. - Adjust in severe renal impairment: use with caution and monitor renal parameters. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Letrozole can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) may markedly lower letrozole levels. - Tamoxifen may antagonize letrozole’s therapeutic effect.

Moderate Interactions (Monitor Closely): - Anticoagulants such as warfarin may increase INR. - Selective serotonin reuptake inhibitors (e.g., fluoxetine) can raise plasma concentrations. - Statins may have altered metabolism when co‑administered.